comparison of glp-1 agonists for weight loss Changes in with RAs in head-to-head clinical studies. *p < View of GLP-1 receptor agonists
Description
Who is at risk of NAFLD
20.Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al

CagriSema: The Future of Weight Loss Medications A deep dive into CagriSema and how it compares to existing treatments: www.patchmd.com/what-is-cagrisema.html

Abstract Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide

Mounjaro has been approved for type 2 diabetes treatment but is not yet available through the NHS

doi: 10.1111/anae.16541
